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The Journal of Immunology
Malat1 Suppresses Immunity to Infection through Promoting
Expression of Maf and IL-10 in Th Cells
James P. Hewitson,*,†,1 Katie A. West,*,†,‡,1 Kylie R. James,x Gulab Fatima Rani,*,‡
Nidhi Dey,*,‡ Audrey Romano,*,‡ Najmeeyah Brown,*,‡ Sarah A. Teichmann,x,{,‖
Paul M. Kaye,*,‡ and Dimitris Lagos*,‡
Despite extensive mapping of long noncoding RNAs in immune cells, their function in vivo remains poorly understood. In this
study, we identify over 100 long noncoding RNAs that are differentially expressed within 24 h of Th1 cell activation. Among those,
we show that suppression of Malat1 is a hallmark of CD4+ T cell activation, but its complete deletion results in more potent
immune responses to infection. This is because Malat12/2 Th1 and Th2 cells express lower levels of the immunosuppressive
cytokine IL-10. In vivo, the reduced CD4+ T cell IL-10 expression in Malat12/2mice underpins enhanced immunity and pathogen
clearance in experimental visceral leishmaniasis (Leishmania donovani) but more severe disease in a model of malaria (Plasmo-
dium chabaudi chabaudi AS). Mechanistically, Malat1 regulates IL-10 through enhancing expression of Maf, a key transcriptional
regulator of IL-10. Maf expression correlates with Malat1 in single Ag-specific Th cells from P. chabaudi chabaudi AS–infected
mice and is downregulated in Malat12/2 Th1 and Th2 cells. The Malat1 RNA is responsible for these effects, as antisense
oligonucleotide-mediated inhibition of Malat1 also suppresses Maf and IL-10 levels. Our results reveal that through promoting
expression of the Maf/IL-10 axis in effector Th cells, Malat1 is a nonredundant regulator of mammalian immunity. The Journal
of Immunology, 2020, 204: 000–000.
L
ong noncoding RNAs (lncRNAs) are .200-nt transcripts
that lack protein-coding potential but have regulatory
functions (1, 2). Mammalian genomes contain thousands
of lncRNAs and demonstrate the highest frequency in lncRNA
transcripts compared with any other species (1). These are mostly
medium to lowly expressed transcripts, displaying poor conser-
vation across mammals. Their modes of action vary, but they often
act as scaffolds, recruiting or sequestering chromatin-modifiers or
RNA-binding proteins (RBPs) to specific genomic sites (2). De-
spite remarkable progress in mapping lncRNAs to mammalian
genomes and exploring lncRNA function at the molecular level in
cellular systems, there is a profound lack of understanding of the
function of lncRNAs (requirement, sufficiency, or redundancy) at
the whole-organism level. For example, although CD4+ Th cells
are central to pathogen-specific adaptive immunity (3), and there
are hundreds of lncRNAs identified as differentially regulated
during CD4+ T cell activation in humans and mice (4–6), fewer
than a handful of lncRNAs have been shown to affect Th cell
function. These include NeST (7), which has been shown to
control its neighboring Ifng locus, and lincR-Ccr2-59 AS (5) and
linc-Maf-4 (6), which affect CD4+ T cell gene expression through
long-range interactions. Therefore, the functional relevance of
lncRNAs in vivo is a largely unexplored and emerging challenge
in both the fields of immunology and RNA biology.
Metastasis-associated lung adenocarcinoma transcript 1 (Malat1)
is a 7.5-kb-long long intergenic noncoding RNA (lincRNA) tran-
script, which is associated with cancer progression and metas-
tasis (8). It is localized in nuclear speckles (9), which are nuclear
foci enriched in factors involved in pre-mRNA splicing and
transcription (10). In contrast to the vast majority of lncRNAs,
Malat1 is highly conserved across mammals and highly and
ubiquitously expressed (5,000–10,000 copies per cell). It has been
somewhat surprising that characterization of three independent
Malat1 knockout (Malat12/2) mouse models did not reveal any
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homeostatic phenotypes (abnormal development, viability, fertility,
or lifespan) or any patent defects in nuclear architecture (e.g.,
speckle formation) (11–13). In the context of CD4+ T cell function,
two recent reports presented contradicting results regarding Malat1
function; Yao and colleagues (14) found that Malat1 does not affect
number of CD4+ T cells and T follicular helper cells or CD8+ T cells
responses to lymphocytic choriomeningitis virus (LCMV) in vivo
and concluded that Malat1 is dispensable for CD4+ T cell function
and development, whereas Masoumi and colleagues (15) reported
that Malat1 is downregulated in tissues from patients with multiple
sclerosis and mice with experimental autoimmune encephalo-
myelitis and that small interfering RNA–mediated knockdown
of Malat1 promoted Th1/Th17 polarization and inhibited T
regulatory cell differentiation in vitro. The above demonstrate
that the physiological function of Malat1 in vivo and potential
role in adaptive immunity remain poorly understood.
In this study, through defining the lncRNA signature of early
Th cell activation, we show thatMalat1 is one of the most highly
abundant transcripts in naive CD4+ T cells and it is downreg-
ulated within the first 24 h of naive CD4+ T cell activation.
Suppression of Malat1 expression is sustained and observed in
in vitro–differentiated Th1 and Th2 cells. Single-cell RNA se-
quencing (RNA-seq) analyses of in vivo–derived Ag-specific
Th1 cells demonstrate that Malat1 expression inversely corre-
lates with expression of transcriptional units involved in RNA
processing and translation, protein degradation, metabolism,
and cellular structure, all hallmarks of Th activation. Similar
correlations are seen in Th2 cells. Conversely, Malat1 expres-
sion positively correlates with expression of Maf (also known as
c-Maf). Functionally, when compared with wild-type (WT) C57BL6
controls, in vitro–generated Malat12/2 Th1 and Th2 cells express
lower levels of Maf and its transcriptional target IL-10. Suppression
of IL-10 expression in Malat12/2 CD4+ T cells is also observed in
mice infected with the protozoan parasite Leishmania donovani or
with Plasmodium chabaudi chabaudi AS (PcAS). Malat12/2 mice
demonstrate enhanced macrophage activation and parasite clear-
ance in the visceral leishmaniasis model, but more pronounced
disease in experimental malaria, similarly to phenotypes observed
in IL-10–deficient mice. Overall, our results demonstrate that
Malat1 suppression is a hallmark of CD4+ T cell activation and
controls IL-10 expression in Th cells. We propose that suppression
of Malat1 in activated CD4+ T cells is a critical determinant of
optimal immunity to chronic infection.
Materials and Methods
Ethics
Animal care and experimental procedures were regulated under the
Animals (Scientific Procedures) Act 1986 (revised under European
Directive 2010/63/EU) and were performed under U.K. Home Office
License (project license number PPL 60/4377 with approval from the
University of York Animal Welfare and Ethical Review Body). Animal
experiments conformed to Animal Research: Reporting of In Vivo
Experiments guidelines.
Mouse infections
Female C57BL/6 CD45.2 mice were obtained from Charles River Labo-
ratories. Malat12/2 mice (complete knockouts) were obtained from the
Riken Institute (12). All mice were bred in-house, maintained under spe-
cific pathogen-free conditions, and used at 6–12 wk of age. The Ethiopian
strain of L. donovani (LV9) was maintained by passage in RAG-22/2
mice. Mice were infected i.v. with 30 3 106 amastigotes via the tail vein.
Parasite burden was expressed parasite count per 100 host cell nuclei or
as Leishman–Donovan units (the number of parasites per 1000 host cell
nuclei 3 organ weight in milligrams).
Female C57BL/6 or Malat12/2 mice (6–12 wk old) were infected with
PcAS through i.v. injection of 1 3 105 parasitized erythrocytes under
reverse light cycles. Parasitemia was monitored from day 5 onwards by
thin blood smears stained with Giemsa stain (infected red cells per 1000
red cells 3 100). Mice were bled within the first 2 h of the dark cycle.
Weights and signs of disease were monitored daily.
FACS analysis and cell sorting
For FACS analysis, spleens were first digested with 0.4 U/ml Liberase TL
(Roche) and 80 U/ml DNase I type IV in HBSS (both Sigma-Aldrich) for
15 min at 37˚C. Enzyme activity was inhibited with 10 mM EDTA (pH 7.5)
and single-cell suspensions were created with 70-mm nylon filters (BD
Biosciences) in complete RPMI 1640 (Thermo Fisher Scientific) supple-
mented with 10% heat-inactivated FCS (HyClone), 100 U/ml penicillin,
100 mg/ml streptomycin, and 2 mM L-glutamine (all Thermo Fisher Sci-
entific). RBCs were lysed with RBC lysing buffer (Sigma-Aldrich). For
live/dead discrimination, cells were washed twice in PBS, then stained
with Zombie Aqua (BioLegend) before resuspension in FACS buffer (PBS
containing 0.5% BSA and 0.05% azide). Fc receptors were blocked with
100 mg/ml rat IgG (Sigma-Aldrich) for 10 min at 4˚C before surface
staining for 30 min at 4˚C. Combinations of the following anti-mouse Abs
were used: CD45.1 allophycocyanin (clone A20); CD45.2 BV786 (104);
CD3 FITC (145-2C11); B220 FITC (RA3-6B2); TCRb PE-Cy7 (H57-
597); MHC class II (MHCII) Alexa Fluor 700 (M5/114.15.2); Ly-6G
PE-Cy7 (1A8); CD11b Pacific Blue and allophycocyanin (M1/70);
CD11c PerCP/Cy5.5 (N418); F4/80 FITC and Alexa Fluor 647 (BM8);
CD44 FITC (IM7); CD62L PE (MEL-14); CD8a allophycocyanin (53-6.7);
CD4 PE and PerCP/Cy5.5 (RM4-5); IFN-g FITC (XMG1.2); IL-10 PE (JES5-
16E3); and IL-17A PE/Cy7 (TC11-18H10.1). All Abs were from BioLegend.
To measure intracellular cytokines in T cells following ex vivo stimu-
lation, cells were first stimulated in complete RPMI 1640 for 4 h at 37˚C
with 500 ng/ml PMA, 1 mg/ml ionomycin, and 10 mg/ml brefeldin A (all
Sigma-Aldrich). For all intracellular cytokine staining, surface stained
cells were fixed and permeabilized (20 min at 4˚C) using Fixation/
Permeabilization Solution before washes in Perm/Wash buffer (both
BD Biosciences). Cells were then stained with intracellular Abs as
above except in Perm/Wash buffer. Appropriate isotype controls were
included. For FACS analysis, events were acquired on an LSRFortessa
(BD Biosciences) before analysis with FlowJo (FlowJo). For cell sorting
of splenic lymphocytes from naive and L. donovani–infected spleens,
CD4+ T cells were sorted as B2202 CD3+ CD4+ CD8a2. For purifi-
cation of naive and activated CD4+ T cells from uninfected mice,
single-cell suspensions were prepared from pooled spleens and pe-
ripheral lymph nodes (axillary, brachial, and inguinal). CD4+ cells were
enriched using CD4 microbeads and LS columns (Miltenyi Biotec) before cell
sorting of naive CD4+ T cells (CD4+ CD62L+ CD442 CD11b2 CD8a2
MHCII2). Cell sorting was performed with a MoFlo Astrios (Beckman
Coulter), and sorted cells were typically .98% positive.
In vitro activation of CD4+ T cells
Purified CD4+ T cells were stimulated with 10 mg/ml plate-bound anti-CD3ε
(clone 145-2C11) and 2 mg/ml soluble anti-CD28 (37.51) in RPMI 1640 as
before in flat-bottom 96-well plates (Th0 conditions). For Th1 polarization,
cells were also treated with 15 ng/ml mouse rIL-12 and 5 mg/ml anti–IL-4
(11B11) or, for Th2 polarization, 30 ng/ml mouse rIL-4 and 5 mg/ml anti–
IFN-g (XMG1.2). To induce suboptimal Th1 differentiation (weakly polar-
izing conditions), 1% of the original stimulation concentrations of
recombinant cytokine rIL-12 and anti–IL-4 were included in the cell
culture medium. To induce suboptimal Th2 differentiation, 2% of the
original concentrations of rIL-4 or anti–IFN-g were included in the
cell culture medium. Anti-CD3/anti-CD28–dependent activation (4 d)
was followed by rest in 10 U/ml human rIL-2 (2 d). To induce Th17
differentiation, naive CD4+ T cells were stimulated with 10 ug/ml
plate-bound anti-CD3 (145-2c11) and 4 mg/ml soluble anti-CD28 (37.51),
and 1 ng/ml of rTGF-b, 37.5 ng/ml rIL-6, 5 mg/ml anti–IFN-g (XMG1.2),
and 5 mg/ml anti–IL-4 (11B11). After 3 d of stimulation, cells were trans-
ferred to a new 96-well plate in the presence of half the concentration of
recombinant cytokines and inhibiting Abs. Cells were harvested and analyzed
by flow cytometry at day 5. All Abs were from BioLegend and were low on
endotoxin and azide free. Recombinant cytokines were from PeproTech.
Control or Malat1-targeting antisense oligonucleotide gapmers were from
QIAGEN (Hilden, Germany; LG00000002-DDA and LG00000008-DDA,
respectively) and were added to naive CD4+ T cells on day 0 at a final
concentration of 100 nM.
Quantitative RT-PCR
RNA was extracted from tissue samples or purified cell populations using
QIAzol and miRNeasy RNA extraction kits (QIAGEN) according to
manufacturer’s instructions. Tissue samples were first dissociated in
QIAzol using a TissueLyser LT with stainless steel beads (all QIAGEN).
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For mRNA transcripts, reverse transcriptions were carried out with Su-
perscript III (Thermo Fisher Scientific) and random hexamer primers
(Promega) and measured with Fast SYBR Green Master Mix (Thermo
Fisher Scientific). PCR were performed using a StepOnePlus Real Time
PCR System (Thermo Fisher Scientific), and relative transcript levels were
determined using the ∆∆Ct method. The following primer sequences were
used: Malat1 forward, 59-TGCAGTGTGCCAATGTTTCG-39; Malat1
reverse, 59-GGCCAGCTGCAAACATTCAA-39; Neat1 forward, 59-CCT-
AGGTTCCGTGCTTCCTC-39; Neat1 reverse, 59-CATCCTCCACAGGC-
TTAC-39; U6 forward, 59-CGCTTCGGCAGCACATATAG-39; and U6
reverse, 59-TTCACGAATTTGGCTGCTAT-39.
For all other genes commercially available, QuantiTect (QIAGEN)
primer sets were used.
RNA-seq analysis
For single-cell RNA-seq analyses, Smart-seq2 single-cell RNA-seq FASTQ
files were obtained from ArrayExpress (www.ebi.ac.uk/arrayexpress/),
accession numbers E-MTAB-4388 (Th1) and E-MTAB-2512 (Th2).
Sequencing reads were mapped to the mouse mm10 Ensembl 84 ref-
erence genome with External RNA Controls Consortium RNA spike-in
sequences using star 2.5.1b and quantified with HTSeq 0.9.1. Nor-
malization and filtering of data were performed using Seurat (version
3.0.0). Cells with expression of fewer than 200 genes and/or a mito-
chondrial read proportion above 5% were excluded from analysis.
Genes were filtered for minimum expression in three cells. Gene
correlations were determined from log-normalized expression data
using cor.test function (stats package) with Spearman rho statistic to
estimate a rank-based measure of association.
Bulk RNA-seq analyses were performed as previously described (16).
Briefly, we compared four naive CD4+ T cells against four activated (24 h)
samples. We obtained 10 million reads per sample on average (range: 4–20
million). Sequence reads were trimmed to remove adaptor sequences with
Cutadapt and mapped to mouse genome GRCm38 with HISAT2, including
rna-strandness FR option. Transcriptome assembly and quantification was
performed using the Tuxedo pipeline (version 2.2.1). Cufflinks was used to
assemble transcriptomes for each sample using the Gene transfer format
annotation file for the GRCm38 mouse genome. This was followed by
running Cuffmerge to merge individual sample transcriptomes into full
transcriptomes. Quantification and normalization were carried out for
each experiment using Cuffquant and Cuffnorm. Differential expression
on gene fragments per kilobase of transcript per million mapped reads
(FPKM) values was performed by conducting paired and independent t
tests with Benjamini–Hochberg false discovery rate correction. Data are
available at Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/
geo/) accession number GSE125268 (wild-type samples only). Gene
ontology and Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING) analysis (http://string-db.org/) were performed where indicated.
STRING settings were highest-confidence interactions only excluding text
mining. Transcription factors and cofactors were extracted by comparing
gene lists to the TFcheckpoint database (http://www.tfcheckpoint.org/).
Western blotting
Cells were washed twice in PBS and protein extracts prepared in radi-
oimmunoprecipitation assay buffer (150 mMNaCl, 10 mM Tris (pH 7.2),
5 mM EDTA, 0.1% SDS, 0.1% Triton X-100, 1% sodium deoxycholate,
1 mM PMSF, 1% protease inhibitor mixture P8340, and 1% phosphate
inhibitor mixtures 2 and 3; all Sigma-Aldrich). Equal total amounts of
protein were resolved on SDS-PAGE gels and transferred to polyvinylidene
difluoride membranes (MilliporeSigma) using a Bio-Rad SD Semi-Dry
Transfer Cell, blocked for 2 h at room temperature in 2% BSA (Thermo
Fisher Scientific) or 5% milk powder (Sigma-Aldrich) in TBST (150 mM
NaCl, 7.7 mM Tris HCl [pH 8], and 0.1% Tween 20; all Sigma-Aldrich)
before overnight probing with primary Abs at 4˚C. Abs were as follows:
Maf (55013-1-AP) and Stat4 (51070-2-AP) from Proteintech, Histone 3
from Cell Signaling Technology. Following extensive washing in TBST,
blots were incubated with secondary Abs (goat anti-rabbit or mouse HRP;
DAKO) for 1 h at room temperature, washed as before, and developed with
ECL Western Blotting Detection Reagent and Hyperfilm ECL (both GE
Healthcare).
Statistical analysis
Statistical analyses were carried out as indicated with Prism 5
(GraphPad Software). Two-way comparisons used paired or unpaired
t tests as indicated, and multiple comparisons used one-way ANOVA,
followed by Bonferroni correction for multiple testing. Any p values
,0.05 were considered significant. All p values are shown when sig-
nificant or borderline.
Results
Malat1 is suppressed at the early stages of CD4+
T cell activation
To gain insight into the role of the noncoding transcriptome in CD4+
T cell function, we began our studies by using bulk RNA-seq to
determine early (24 h) changes in expression of lncRNAs under
in vitro Th1-polarizing conditions. We identified 120 differentially
expressed lncRNAs, the majority of which were intergenic, dis-
tributed across the genome (Fig. 1A). As expression of lncRNAs
varied (Fig. 1B), we set an additional criterion in our analysis and
identified 23 lncRNAs that were expressed in CD4+ T cells at
FPKM . 20 and were differentially regulated (log2 fold change
[LFC] . 1 or LFC , 21) between naive and 24-h-activated CD4+
T cells (Fig. 1C, 1D). We observed a significant correlation between
changes in expression of the identified lncRNAs and their chro-
mosomally adjacent genes (Supplemental Fig. 1A), which inferred
the existence lncRNA-mediated in cis regulatory effects across the
CD4+ T cell transcriptome, in agreement with previous studies (1).
We further investigated the list of highly expressed and differ-
entially regulated lncRNAs and noticed that Malat1 (Fig. 1C) was
the most highly expressed dysregulated lncRNA that was also
conserved between the mouse and human genome (Gm26917 and
Gm26836 were expressed at higher levels than Malat1 but have no
obvious sequence or syntenic homologs in the human genome). Of
note, Malat1 was within the top 2% most highly expressed tran-
scripts in naive CD4+ T cells (Supplemental Fig. 1B). Malat1
suppression was confirmed by quantitative RT-PCR (qRTPCR)
(Fig. 1E). Neat1, an lincRNA adjacent to Malat1 in both mouse
and human genome, was also found to be significantly downreg-
ulated within 24 h of CD4+ T cell activation by qRTPCR (Fig.
1E). The downregulation of Neat1 upon CD4+ T cell activation
did not reach statistical significance in our RNA-seq analysis,
likely because of higher variation and lower absolute expression
of Neat1 compared with Malat1 in CD4+ T cells (Supplemental
Fig. 1C). Suppression of Malat1 and Neat1 expression were also
observed in end point (day 6) differentiated Th0-, Th1-, and Th2-
polarizing conditions in vitro (Fig. 1F). Both Malat1 and Neat1
were downregulated within hours of naive CD4+ T cell activation
(Fig. 1G, Supplemental Fig. 1D). The above results revealed that
the rapid suppression of Malat1 and Neat1 expression is a key
feature of the early lncRNA signature of CD4+ T cell activation.
Malat1 suppression is a transcriptomic hallmark of CD4+
T cell activation
To gain insight into whether Malat1 suppression was associated
with CD4+ T cell function, we first analyzed a single-cell RNA-
seq dataset we previously published exploring emergence of Th1
cells in vivo (17) using Plasmodium-specific TCR transgenic
CD4+ T (PbTII) cells transferred into congenically labeled mice
and recovered at days 2, 3, 4, and 7 postinfection (p.i.) with PcAS.
In agreement with the observed suppression of Malat1 in our
in vitro experiments (Fig. 1), we observed Malat1 and Neat1
downregulation upon CD4+ T cell activation in vivo, reaching a
minimum at days 3 and 4, followed by a relative increase by day 7
(Fig. 2A, 2B). As observed in vitro, Neat1 expression was lower
than Malat1 in Th1 cells in vivo (Fig. 2A, 2B).
Next, we searched for transcriptomic units that show significant
correlation with Malat1 expression at the single-cell level. We
performed these analyses using the data from PbTII CD4+ T cells
at day 7 p.i. because this is the time point that the strongest Th1
responses are observed (17). Analyses were performed in gated
Th1 cells based on IFN-g and CXCR6 expression rather than all
CD4 PbTII cells at this time point. We searched for genes, the
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expression of which was positively or negatively correlated with
that of Malat1. Strikingly, we found that from 687 genes that
demonstrated significant correlation with Malat1 in Th1 cells, 609
(88.6%) correlated negatively (i.e., cells with low Malat1 levels
demonstrate high levels of these genes). We noted that this was not
purely due to the fact thatMalat1 is downregulated in Th1 cells, as
performing the same analysis for Lncpint, an lincRNAwith similar
basal expression in CD4+ T cells that is also downregulated upon
activation (Fig. 1C) did not show a similar bias toward negative
correlation (Supplemental Fig. 2A). Neat1 was within the posi-
tively correlated genes (Supplemental Fig. 2B), consistent with
reports showing that the two lincRNAs are coregulated (18). Gene
ontology analysis of the negatively correlated genes revealed
significant enrichment in genes involved in RNA binding, ribo-
somal function, metabolism, and cellular structure/localization
(Fig. 2C). We noted that these were processes associated with
cellular activation and specifically naive CD4+ T cell differentia-
tion to effector Th cells (19, 20). Analysis of a published set of
FIGURE 1. Identification of differentially regulated lncRNAs upon activation of naive CD4+ T cells reveals Malat1 suppression as a hallmark of Th cell
activation. (A) LFC of statistically significantly differentially regulated lncRNAs (false discovery rate, 0.05) per chromosome following 24 h activation of
naive CD4+ T cells under Th1 conditions. Expression determined by bulk RNA-seq (n = 4). (B) Distribution of lncRNA expression in naive and activated
(24 h, Th1 conditions) CD4+ T cells. (C) Expression versus LFC for all the differentially regulated lncRNAs. Dotted lines indicate LFC = 1 and FPKM = 20.
(D) Expression heatmap of most highly expressed and differentially expressed lncRNAs. For downregulated, lncRNAs with LFC . 1 and naive CD4+
FPKM . 20 are shown. For upregulated, lncRNAs with LFC . 1 and Th1-activated CD4+ FPKM . 20 are shown. (E) Expression of Malat1 and Neat1 in
naive and Th1-activated CD4+ T cells (24 h postactivation) determined by qRTPCR. Expression is normalized to U6 RNA and average expression in naive
CD4+ T cells. (F) Malat1 expression determined in in vitro–differentiated Th0, Th1, and Th2 cells (day 6). Expression is normalized to U6 RNA and
average expression in naive CD4+ T cells. (G) Malat1 expression during in vitro Th1 differentiation, normalized to naive CD4+ T cells.
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FIGURE 2. Transcriptional units and transcription factors correlating with Malat1 expression at single-cell level in Th cells in vivo. (A) Normalized
transcript counts of Malat1 in single Plasmodium-specific CD4+ T (PbTII) cells isolated at the indicated timepoints following infection with PcAS. Mean
and 95% confidence intervals are shown. (B) Normalized transcript counts of Neat1 in single PbTII cells isolated at the indicated timepoints following
infection with PcAS. Mean and 95% confidence intervals are shown. (C) Most highly enriched gene ontology (GO) terms among significantly negatively
correlated (p , 0.05) genes with Malat1 in PbTII cells isolated from PcAS-infected mice (7 d p.i.). (D) Heatmap of correlation coefficients of Malat1 and
indicated Malat1-interacting mRNAs (21, cell) in single PbTII cells from PcAS-infected mice 7 d p.i. (E) Correlation coefficient of Malat1 and indicated
Malat1-interacting mRNAs (left y-axis, red) in single PbTII cells from PcAS-infected mice (7 d p.i.) versus average LFC following 24 h Th1 in vitro
activation of naive CD4+ T cells (right y-axis, blue). Values are shown for significantly differentially expressed genes (FDR , 0.05) following 24 h Th1
activation of naive CD4+ T cells. (F) Most highly enriched GO terms among significantly negatively correlated (p , 0.01) genes with Malat1 in single
in vitro–differentiated Th2 cells. (G) STRING network of significantly correlated genes with Malat1 at single-cell levels in both in vivo PbTII Th1 and
in vitro Th2 cells. Functional clusters are numbered and shown.
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Malat1-interacting mRNAs in embryonic stem cells (21) indicated
that Malat1 has the potential to interact with the mRNA of 43 of
the coregulated genes (Fig. 2D). Notably, 19 of these genes were also
statistically significantly differentially expressed within 24 h of Th1
activation, with a dominant trend toward upregulation (Fig. 2E).
To assess whether the aboveMalat1-correlated gene signatures were
specific to Th1 cells, we analyzed a single-cell RNA-seq dataset we
previously published exploring gene expression in in vitro–polarized
Th2 cells (22). Malat1 expression was significantly correlated with a
higher number of genes in in vitro–differentiated Th2 cells (1946) than
in Th1 cells from the PcAS-infected mice. As in the case of Th1 cells,
the majority of statically significant correlations between expression of
Malat1 and other genes were negative (1455 out of 1946, 74.8%).
Similarly, to the observed results with Th1 cells, there was again a
positive correlation between Malat1 and Neat1 (Supplemental Fig.
2C). Of note, Neat1 was the only gene neighboring Malat1 that
showed a significant correlation with Malat1 in both Th1 and Th2
cells (Supplemental Fig. 2D), suggesting thatMalat1 has limited in cis
regulatory effects in Th cells. This was further supported by expres-
sion analyses inWT andMalat12/2 cells for Neat1 and Scyl1, the two
chromosomally adjacent genes to Malat1. Neat1 levels were lower in
naive Malat12/2 CD4+ T cells, and Scyl1 levels were higher in
in vitro–differentiated Malat12/2 Th2 cells, but these effects were not
consistent among the three cell types (Supplemental Fig. 2E). As in
the case of single Th1 cells, gene ontology analysis of the negatively
correlated genes revealed again significant enrichment in genes in-
volved in RNA binding, ribosomal function, metabolism, and cell
cycle (Fig. 2F). There were 152 genes that were significantly corre-
lated with Malat1 in both single Th1 and Th2 cell–formed functional
clusters with roles in RNA processing, ribosomal function, meta-
bolism, and protein degradation (Fig. 2G, Supplemental Fig. 2F).
Overall, these results indicated that, at the single-cell level, Malat1
suppression in Th cells correlated with induction of key gene networks
upon CD4+ T cell activation.
Malat1 controls IL-10 expression in Th cells in vitro
Having found that Malat1 suppression is a hallmark of Th acti-
vation, we tested the effect of Malat1 deletion on Th activation.
We found that following in vitro differentiation of naive CD4+
T cells to Th1, Malat12/2 cells displayed a reduction in levels of
IFN-g that did not reach statistical significance but significantly
reduced expression of the immunoregulatory cytokine IL-10.
Upon Th2 differentiation, there was also a significant reduction
in IL-10 levels, with IL-4 being unaffected (Fig. 3A–C). The ef-
fect on IL-10 was more prominent in Th2 cells, which express
higher levels of IL-10 than Th1 cells in vitro (Fig. 3A, 3B). We
also observed a reduction in IL-10 mRNA levels (Fig. 3D). We
repeated these experiments under weakly polarizing conditions
and found a statistically significant reduction upon Malat1 loss on
IFN-g expression in suboptimally activated Th1 cells but no ef-
fects on IL-10 or IL-4 and Il-10 under weakly polarizing Th2
conditions (Supplemental Fig. 3A). Malat1 loss also suppressed
IL-10 and IL-17 expression under Th17-differentiation conditions
(Supplemental Fig. 3B). In addition to genetic knockout of
Malat1, targeting the RNA product of Malat1 with antisense oli-
gonucleotide gapmers also suppressed IL-10 at the mRNA level in
both Th1 and Th2 cells (Fig. 3E, 3F). The effect was also observed
at the protein level in Th2 cells (Fig. 3G). In Th1 cells, gapmer-
mediated inhibition of Malat1 resulted in a significant decrease in
IFN-g expression with no effects on IL-10 (Fig. 3H). Notably, we
found that the suppression of IL-10 expression occurred in
Malat12/2 CD4+ T cells irrespectively of how many times they
have divided (Fig. 3I, 3J), demonstrating that the effect of Malat1
on IL-10 is decoupled from Th cell proliferation. Overall, these
results demonstrated that Malat1 deficiency results in altered
effector Th cell differentiation and cytokine expression in vitro,
with a common effect among Th1, Th2, and Th17 cells being
suppression of IL-10.
Loss of Malat1 impairs Maf expression in Th cells
To explore the mechanism employed by Malat1 to regulate IL-10,
we determined the effect of Malat1 on transcription factors as-
sociated with Th cell activation and differentiation. Analysis of
our single-cell RNA-seq data revealed 25 transcription factors that
showed a significant correlation with Malat1 expression in Th1
cells from PcAS-infected mice (Fig. 4A). Notably, one of only
three transcription factors that showed positive correlation with
Malat1 was Maf (also known as c-Maf; Fig. 4B), a protein with
fundamental roles in CD4+ T cell biology and, notably, an es-
sential transcriptional regulator of IL-10 expression in Th cells
(23–28). We also observed a positive correlation between Malat1
and Maf in single Th2 cells, which was borderline statistically
nonsignificant (p = 0.0504; Fig. 4C). Despite a lack of a positive
correlation between Malat1 and IL-10 in our single-cell analyses,
possibly because of the low number of IL-10–expressing cells in
the analyzed datasets (Supplemental Fig. 3C), Maf was one of
only five genes positively correlating with expression of IL-10 and
Malat1 in single Plasmodium-specific CD4+ T PbTII cells
(Supplemental Fig. 3D). Investigating a list of previously pub-
lished transcription factors correlating with IL-10 expression in
CD4+ T cells (23) for overlap with genes correlated with Malat1
in single CD4+ T PbTII cells also identified Maf as the only gene
present in both sets.
Next, we tested the effect of lack of Malat1 on levels of tran-
scription factors with key roles in Th cell differentiation. Malat1
did not affect levels of Tbet in Th1 cells or Gata3 in Th2 cells
(Supplemental Fig. 3E, 3F). However, Maf levels were reduced in
both Th1 and Th2 cells, the effect reaching statistical significance
in Th2 cells (Fig. 4D), which express higher levels of Maf than
Th1 cells in vitro (Supplemental Fig. 3G). InMalat12/2 Th1 cells,
we also observed a significant downregulation of Stat4 (Fig. 4E),
with no changes observed in Stat6 in Th2 cells (Supplemental
Fig. 3H). Of note, Stat4 is also known to promote IL-10 tran-
scription in Th1 cells (29) and was also downregulated in
Malat12/2 Th1 cells. At the protein level, we observed only a
modest suppression of Stat4 expression in Malat12/2 Th1 cells
at day 6 (Fig. 4F), whereas suppression of Maf was more pro-
nounced than that observed at the mRNA level (Fig. 4D). Of
note, the kinetics of Maf mRNA levels in Th1 cells demon-
strated an early reduction followed by an increase (Fig. 4G),
suggesting that Malat1 might be playing a role in Maf regulation
at both the early and later stages of Th1 differentiation. Knock-
down of Malat1 with gapmers suppressed Maf levels in both Th1
and Th2 cells, demonstrating that the effect is mediated by the
Malat1 RNA (Fig. 4H). Furthermore, levels of Bhlhe40, a tran-
scription factor involved IL-10 regulation (30) and anticorrelating
with Malat1 (Fig. 4A), were not affected in Malat12/2 Th1 or Th2
cells (Supplemental Fig. 3I). Taken together, the above demonstrate
that Malat1 loss suppresses expression of Maf, a central transcrip-
tional regulator of IL-10 in Th cells.
Malat12/2 mice infected with L. donovani demonstrate
reduced IL-10 expression in CD4+ T cells and lower
parasite burden
Next, to explore the functional role of Malat1/Maf/IL-10 pathway
in vivo, we studied the role ofMalat1 in infection models in which
IL-10 deficiency either promotes pathogen clearance or enhances
immunopathology. First, we used L. donovani infection of mice as
6 Malat1 LOSS SUPPRESSES IL-10 AND PROMOTES Th CELL IMMUNITY
 at U
niversity of Y
ork on M
ay 5, 2020
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
a model of pathogen-induced chronic inflammation (31). We
chose to study a model of visceral leishmaniasis because Th1 cell–
derived IL-10 has been previously shown to be a critical for
protection and pathogen clearance but also a critical determinant
of disease outcomes in humans (16, 32–36). Malat1 expression
was reduced in CD4+ T cells isolated from spleens of infected
mice compared with naive CD4+ T cells (Fig. 5A). Critically, we
found that at the chronic infection stages (day 42 p.i.), IL-10
expression was reduced in splenic CD4+ T cells from infected
Malat12/2 mice without any changes in IFN-g expression
FIGURE 3. Loss of Malat1 in in vitro–differentiated Th1 and Th2 cells results in suppression of IL-10 expression. (A) Representative FACS plots of
IL-10 and IFN-g or IL-10 and IL-4 expression in in vitro–differentiated Th1 and Th2 cells (day 6), respectively. (B) Percentage of IL-10+ live TCRb+ CD4+
WT (blue) orMalat12/2 (red) Th1 or Th2 cells. Levels determined by intracellular cytokine staining. Levels in Th0 cells shown for reference (n = 6 for Th1
and Th2, and n = 3 for Th0). (C) Percentage of IFN-g+ or IL-4+ live TCRb+ CD4+ WT (blue) or Malat12/2 (red) Th1 or Th2 cells, respectively. Levels
determined by intracellular cytokine staining. Levels in Th0 cells shown for reference (n = 6 for Th1 and Th2, and n = 3 for Th0). (D) IL-10mRNA levels in
in vitro–differentiated WT (blue) or Malat12/2 (red) Th1 and Th2 cells (day 6) determined by qRTPCR. Levels normalized to U6 and average levels in WT
cells. (E) IL-10, IFN-g, and Malat1 RNA levels in in vitro–differentiated Th1 cells (day 6) transfected with control (blue) or Malat1-targeting (brown)
gapmer (100 nM). Levels normalized to U6 and average levels in cells transfected with control gapmer. (F) IL-10, IL-4, and Malat1 RNA levels in in vitro–
differentiated Th2 cells (day 6) transfected with control (blue) or Malat1-targeting (brown) gapmer (100 nM). Levels normalized to U6 and average levels
in cells transfected with control gapmer. (G) Percentage of IL-10+ live TCRb+ CD4+ Th1 or Th2 cells transfected with control (blue) or Malat1-targeting
(brown) gapmer (100 nM). Levels determined by intracellular cytokine staining on day 6. (H) Percentage of IFN-g+ live TCRb+ CD4+ Th1 cells transfected
with control (blue) or Malat1-targeting (brown) gapmer (100 nM) (n = 4). (I) Percentage of IL-10+ CD4+ WT (blue) or Malat12/2 (red) Th1 cells (day 6)
per cell division as determined by intracellular cytokine and CFSE staining (n = 4). (J) Percentage of IL-10+ CD4+ WT (blue) or Malat12/2 (red) Th2 cells
(day 6) per cell division as determined by intracellular cytokine and CFSE staining (n = 4).
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(Fig. 5B–D), mirroring our findings from in vitro–activated
CD4+ T cells (Fig. 4). There were no statistically significant
changes in the number of splenic CD4+ T cells or frequency of
naive (CD62L+/CD442) and effector cells (CD62L2/CD44+)
CD4+ T cells between WT and Malat12/2 mice (Supplemental
Fig. 4A, 4B). The reduction in IL-10+ Th1 cells was accom-
panied with increased inducible NO synthase expression from
splenic myeloid cells, particularly CD11b+/CCR2+/Ly-6Chi
inflammatory monocytes in Malat12/2 mice (Fig. 5E). No changes
in MHCII or IL-10 were found in any of the myeloid populations
(Supplemental Fig. 4C, 4D). Critically, the observed reduction in
IL-10 levels was accompanied by significantly reduced parasite
loads in Malat12/2 mice (Fig. 5F, 5G) without any significant
effects on spleen or liver size (Supplemental Fig. 4E). These re-
sults demonstrated that Malat1 regulates IL-10 in Th cells in vivo
and that Malat1 deficiency can lead to enhanced protection during
chronic L. donovani chronic infection.
PcAS-infected Malat12/2 mice demonstrate reduced Th1 IL-10
expression and more severe disease
To further test the functional relevance of Malat1-mediated IL-10
regulation in vivo, we infected Malat12/2 and WT mice with
PcAS. IL-10 plays a prominent role in the outcome of malaria
disease in humans (37, 38), and in the PcAS experimental model
of malaria, IL-10 deficiency promotes severe disease manifested
as more pronounced weight loss and mortality (39). As in the case
FIGURE 4. Malat1 regulates Maf in Th cells. (A) Heatmap of correlation coefficients of significantly correlated transcription factors and coactivators
(p, 0.05) and Malat1 expression by single PbTII cells isolated from PcAS-infected mice at day 7 p.i. (B) Normalized transcript count ofMalat1 versus
Maf in single PbTII cells isolated from PcAS-infected mice at day 7 p.i. (C) Normalized transcript count of Malat1 versus Maf in single in vitro–
differentiated Th2 cells. (D) Maf mRNA levels in in vitro–differentiated WT (blue) or Malat12/2 (red) Th1 and Th2 cells (day 6) determined by qRTPCR.
(E) Stat4 mRNA levels in in vitro–differentiated WT (blue) or Malat12/2 (red) Th1 cells (day 6). In (D) and (E), levels are determined by qRTPCR (n = 7)
and normalized to U6 and average levels in WT cells. (F) Maf and Stat4 protein levels in WT (blue) or Malat12/2 (red) Th1 cells at days 4 or 6 post-
activation determined by Western blot. (G) Maf mRNA levels during in vitro Th1 differentiation, normalized to naive CD4+ T cells. Levels normalized to
U6 and average levels in naive CD4+ T cells. (H) Maf mRNA levels in Th1 or Th2 cells transfected with control (blue) orMalat1-targeting (brown) gapmer
(100 nM). Levels normalized to U6 and average levels in cells transfected with control gapmer.
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of L. donovani infection, CD4+ T cells from spleens of PcAS-
infected Malat12/2 mice demonstrated lower IL-10 expression
(Fig. 6A, 6B). A borderline nonsignificant trend toward reduction
in IFN-g+ CD4+ T cells was also observed (Fig. 6C). Crucially,
more pronounced weight loss was observed in Malat12/2 mice
compared with WT controls within the first week of PcAS infec-
tion (Fig. 6D). Of note, the experiment had to be terminated be-
cause of the increased rate of weight loss in Malat12/2 mice
(expected to exceed 20% of starting body weight by day 9) and
lack of touch escape and pinna reflexes in Malat12/2 at day 8
(median score of 0 out of 2 for both). We did not observe any
effects on parasitemia (Fig. 6E). Spleen enlargement was similar
between WT and Malat12/2 mice, but a modest reduction liver
size in PcAS-infected Malat12/2 mice was observed (Fig. 6F). Of
note,Malat1 did not affect IL-10 and IFN-g levels in CD8+ T cells
in infected mice (Supplemental Fig. 4F, 4G). The above findings
FIGURE 5. Loss of Malat1 results in suppression of IL-10 expression in Th1 cells in vivo and enhanced immunity to L. donovani. (A) Malat1 levels
determined by qRTPCR in naive (N) CD4+ T cells and CD4+ T cells isolated from spleens of L. donovani–infected mice (day 28) p.i. Levels normalized to
U6 and average levels in N CD4+ T cells. (B) Representative FACS plots of IL-10 and IFN-g expression in splenic CD4+ T cells from L. donovani–infected
WT and Malat12/2 mice (day 42 p.i.) following restimulation with PMA/ionomycin. (C) Percentage of IL-10+ live TCRb+ CD4+ cells from L. donovani–
infectedWT (blue) or Malat12/2 (red) mice (day 42 p.i.), determined by intracellular cytokine staining. Levels from noninfected N mice are also shown for
reference. Levels are shown in cells directly postisolation (brefeldin A [bref] alone) or following restimulation with PMA and ionomycin (PMA/iono).
(D) Percentage of IFN-g+ live TCRb+ CD4+ cells from L. donovani infected WT (blue) or Malat12/2 (red) mice (day 42 p.i.), determined by intracellular
cytokine staining. Levels from noninfected N mice are also shown for reference. Levels are shown in cells directly postisolation (bref alone) or following
restimulation with PMA/iono. (E) Percentage of inducible NO synthase-positive (iNOS+) myeloid live cells from spleens of noninfected (N) or
L. donovani–infectedWT (blue) orMalat12/2 (red) mice (day 42 p.i.; n = 5). (F) Spleen and liver parasite counts per 1000 nuclei from L. donovani–infected
WT (blue) or Malat12/2 (red) mice (day 42 p.i.). (G) Spleen and liver Leishman–Donovan units from L. donovani–infected WT (blue) or Malat12/2 (red)
mice (day 42 p.i.). For (C), (D), (F), and (G), n = 11, and for (E), n = 5.
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further demonstrated the role ofMalat1 in regulation of IL-10 in
Th cells in vivo and supported that the extent of Malat1
downregulation and its expression kinetics during Plasmodium
infections can be a significant determinant of infectious disease
outcome.
Discussion
Despite its high abundance and conservation, the physiological
function of Malat1 at the whole organism level has remained
elusive. We demonstrate that regulation of adaptive immunity is
one of the essential functions of this unique noncoding RNA. We
show that suppression ofMalat1, one of the most highly expressed
transcripts in naive CD4+ T cells, is a hallmark of Th1 and Th2
activation, but its complete deletion results in altered Th cell
phenotype and enhanced Th cell responses in vivo, which can lead
to protection from infection but also severe immunopathology. It
is possible that suppression of Malat1 can be due to dilution oc-
curring during the initial transcriptional burst at the early stages of
naive CD4+ T cell activation. This would mean that there are
transcriptional mechanisms excluding Malat1, a very highly
expressed and transcribed transcript, from this general burst. We
note that these mechanisms would be specific to Malat1, as we
show that the expression of other highly expressed lncRNAs is not
altered or diluted upon naive CD4+ T cell activation (Fig. 1C).
Furthermore, Malat1 suppression is sustained up to 6 d post-
activation, suggesting the existence of active transcriptional sup-
pression and/or posttranscriptional destabilization mechanisms
regulating its expression in Th cells. The observed inverse cor-
relation between Malat1 expression and transcriptional signatures
associated with cellular activation in single Th cells might signify
that high Malat1 expression is necessary for maintenance of
the naive CD4+ T cell state or that suppressed Malat1 expression
is required for appropriate Th cell differentiation. The seeming
contradiction between our findings and those reported by Yao and
colleagues (14) during acute LCMV infection can be explained by
the predominant focus of that study on CD8+ T cell responses and
the fact that IL-10 determines susceptibility to infection only in
chronic LCMV infection models (40). In our study, the effect of
Malat1 on IL-10 expression is observed both in in vitro differ-
entiated Th cells and in vivo in two distinct infection models
progressing at significantly different timescales (days for PcAS
versus weeks for L. donovani), demonstrating a CD4+ T cell–
intrinsic regulatory role for Malat1. We note that because of the use
of a full Malat12/2 mouse, we cannot exclude other CD4+ T cell–
independent mechanism contributing to L. donovani clearance or
PcAS-induced immunopathology. However, we propose that despite
its widespread expression across tissues, Malat1 has striking CD4+
T cell–specific functions, one of which involves promoting Maf and
IL-10 expression.
It is thought that Malat1 controls gene expression through
interacting with multiple RBPs (9, 21, 41, 42). Our experiments
with Malat1 inhibitors confirmed that the Malat1 RNA is re-
sponsible for altered Th cell differentiation. We note that we ob-
served slight differences between the effect of Malat1 knockout
and that of knockdown in Th1 cells (e.g., with regards to IFN-g
expression). These observations can be the result of the fact that
Malat1 is deleted in naive CD4+ TMalat12/2 cells before they are
activated, whereas in cells treated with gapmers, depletion occurs
concurrently with activation and endogenous downregulation of
Malat1. In any case, we show that inhibiting or deleting Malat1
can lead to reduction of IL-10 and Maf expression in vitro and
in vivo. We propose that the specificity of Malat1 functions in
CD4+ T cells is mediated through a network of interactions be-
tween Malat1 and RBPs, which, in turn, have cell-type specific
RNA targets and functions (43). Indeed, we anticipate that Malat1
functions in Th cell differentiation are likely to extend beyond
regulation of Maf and IL-10. The work presented in this study
reveals one mechanism employed byMalat1 to shape immunity to
FIGURE 6. Loss of Malat1 results in suppres-
sion of IL-10 expression in Th1 cells and more
severe disease in PcAS-infected mice. (A) Per-
centage of IL-10+ live TCRb+ CD4+ cells from
PcAS-infected WT (blue) or Malat12/2 (red) mice
(day 8 p.i.), determined by intracellular cytokine
staining. Levels from noninfected naive (N) mice
are also shown for reference. Levels are shown
in cells directly postisolation (brefeldin A [bref]
alone) or following restimulation with PMA and
ionomycin (PMA/iono). (B) As in (A) but for per-
centage of IFN-g+/IL-10+ live TCRb+ CD4+ cells
from PcAS-infected WT (blue) or Malat12/2 (red)
mice (day 8 p.i.). (C) As in (A) but for percentage of
IFN-g2/IL-10+ live TCRb+ CD4+ cells from PcAS-
infected WT (blue) or Malat12/2 (red) mice (day 8
p.i.). (D) Body weight of PcAS-infected WT
(B6, blue) or Malat12/2 (red) mice on indicated
days p.i. Weight expressed as percentage of starting
weight for each mouse. Black line shows weights of
noninfected mice. *p , 0.05, **p , 0.01, between
infected WT and Malat12/2 mice. (E) Parasitemia
(percentage of infected cells) in PcAS-infected WT
(B6, blue) or Malat12/2 (red) mice on indicated
days p.i. (F) Spleen and liver weights as per-
centage of body weight in PcAS-infected WT
(B6, blue) or Malat12 /2 (red) mice at day 8 p.i.
For (A)–(F), n = 4–6.
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infection and indicates that this lncRNA, like IL-10, plays a critical
role in controlling the fragile equilibrium between effective patho-
gen clearance and enhanced immunopathology. Our work suggests
that exploring how Malat1-binding RBPs regulate Maf and IL-10
expression through Malat1-dependent or -independent mechanisms
can provide key insight into the posttranscriptional regulation of this
critical immunoregulatory axis.
Implicating Malat1 in the regulation of IL-10 can have far-
reaching consequences. Although all activated (effector and
regulatory) CD4+ T cells express IL-10 at some point of their
differentiation trajectory (26), the magnitude and kinetics of
expression differ drastically between subsets. Yet, despite sig-
nificant progress on the transcriptional cues that initiate and
maintain IL-10 expression in CD4+ T cells, much less is known
about the molecular controllers that ensure accurate timing and
magnitude of IL-10 expression. Our work supports that Malat1
plays a key role in the complex process that ensures optimal IL-10
levels. Notably, the high abundance of Malat1 in naive CD4+
T cells is evolutionary-compatible with this role. Although Malat1
expression is reduced early during CD4+ T cell activation, its high
absolute abundance means that there is still a significantMalat1 pool
within effector Th cells to allow for appropriate IL-10 expression.
This provides a flexible molecular mechanism of regulating immune
responses mediated by Malat1, a major component of the CD4+
T cell noncoding transcriptome. Although predominantly focused on
Th1 and Th2 cells, our work suggests that Malat1 might be a sig-
nificant functional determinant of other Maf- and IL-10–expressing
immune cell types, such as regulatory T cells (44), follicular Th cells
(45, 46), or innate lymphoid cells (47).
Overall, our findings reveal Malat1 as a negative regulator of
immunity to infection. We uncover the functional significance of
Malat1 in the context of two major parasitic infectious diseases,
malaria and visceral leishmaniasis, providing new insight into
molecular determinants of disease susceptibility. We speculate
that through its fundamental role in Th cell differentiation and
function,Malat1 is likely to govern immune responses and disease
outcomes in a broad range of infectious, autoimmune, or inflam-
matory pathological conditions, reflecting the centrality of the
noncoding transcriptome in the immune system.
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